Improving existing drugs to provide better options to patients at a reasonable cost

Focused on Patients' Well-Being

Opportunities

  • More than 60% of the marketed drugs have problems with either solubility, permeability or both.

  • These drugs are not utilized to their full potential

Solutions

  • ​​Sarfez is developing innovative technologies to improve these drugs

  • Short development duration, modest investment, and lower risk are the hallmarks of Sarfez's strategy

  • Sarfez is committed to providing improved drugs at affordable prices

 

 

 
 
Technology
 
Custom solutions for unique problems

 

For drugs that have short duration of action and have to be taken more than once a day

Rapid-action Orally-disintegrating Technology (ROTEC)

For drugs that take too long to act but are needed for quick relief

Self Emulsifying Drug Delivery System (SEEDS)

For poorly permeable and extensively metabolized drugs that are taken in large dosage

Pipeline
Cardio-renal products specialist

Long-acting loop Diuretics

Chronic Congestive Heart Failure

Close to NDA stage 

Expected filing Q2 2018

Better bioavailable direct renin inhibitor

 

Nephrotic Syndrome (FSGS) 

Early clinical stage

Expected NDA filing Q3 2019

Improved mineralocorticoid receptor antagonist

Diabetic Nephropathy

Early clinical stage

Expected NDA filing Q1 2019

Fast-acting Mu receptor agonist

 

Migraine Onset

Late pre-clinical stage

Expected NDA filing Q2 2020

Cardiovascular and Renal Products Focused Company

 

Matrix-based Extended Release (MEXFOR)

Leveraging alliances

  • Virtual model to maximize cost efficiencies

  • Alliances with specialized and best-in-the class companies

  • Government non-diluted funding

  • Academic knowledge and expertise

  • Patient experiences to develop optimal solutions

 
Strategy
 
Clinic to lab and back to clinic
 

Management

Scientific Advisors

 
Team
 
Academically oriented and patient-focused

Fatima Khwaja, PhD

Chief Executive Officer

Bertram Pitt, MD                                Chief of Scientific Advisory Board

Craig Brater, MD

Scientific Advisor

Domenic Sica, MD

Scientific Advisor

Christopher Wilcox, MD, PhD

Chief Scientific Advisor

Guru Betageri, PhD

Scientific Advisor

Salim Shah, PhD, JD

Founder and Chairman

Contact Us

 
Sarfez Pharmaceuticals Inc

8000 Towers Crescent Drive, Suite 1350, Vienna VA 22182

(703) 627-1934

 

Follow

  • Facebook
  • Twitter
  • LinkedIn

Contact

info@sarfez.com

(703) 627-1934

Address

8000 Towers Crescent Drive

Suite 1388

Vienna, VA 22182

    ©2020 by Sarfez Pharmaceuticals, Inc.